OrbiMed’s Syndax Pharmaceuticals SNDX Stock Holding History

OrbiMed’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.5M	Buy	+962,300	New	+$20.9M	0.45%	53
2024 Q4	–	Sell	-1,925,300	Closed	-$37.1M	–	137
2024 Q3	$37.1M	Hold	1,925,300	–	–	0.67%	42
2024 Q2	$39.5M	Buy	1,925,300 +176,300	+10%	+$3.69M	0.78%	42
2024 Q1	$41.6M	Hold	1,749,000	–	–	0.76%	44
2023 Q4	$37.8M	Buy	1,749,000 +465,000	+36%	+$7.15M	0.75%	44
2023 Q3	$18.6M	Sell	1,284,000 -1,246,240	-49%	-$23.6M	0.4%	65
2023 Q2	$53M	Buy	2,530,240 +818,565	+48%	+$17M	0.96%	39
2023 Q1	$36.2M	Sell	1,711,675 -294,825	-15%	-$7.33M	0.71%	46
2022 Q4	$51.1M	Hold	2,006,500	–	–	0.98%	39
2022 Q3	$48.2K	Sell	2,006,500 -316,800	-14%	-$7.11M	0.9%	43
2022 Q2	$44.7K	Buy	2,323,300 +165,000	+8%	+$2.75M	0.81%	39
2022 Q1	$37.5M	Buy	2,158,300 +177,000	+9%	+$2.98M	0.61%	47
2021 Q4	$43.4M	Buy	1,981,300 +1,790,700	+940%	+$33.1M	0.56%	52
2021 Q3	$3.64M	Buy	+190,600	New	+$3.18M	0.04%	159
2021 Q1	–	Sell	-1,170,900	Closed	-$26M	–	177
2020 Q4	$26M	Buy	1,170,900 +76,800	+7%	+$1.59M	0.23%	89
2020 Q3	$16.1M	Hold	1,094,100	–	–	0.2%	95
2020 Q2	$16.2M	Buy	1,094,100 +804,100	+277%	+$12.2M	0.23%	84
2020 Q1	$3.18M	Buy	290,000 +78,000	+37%	+$732K	0.05%	118
2019 Q4	$1.86M	Hold	212,000	–	–	0.03%	119
2019 Q3	$1.58M	Hold	212,000	–	–	0.03%	110
2019 Q2	$1.97M	Hold	212,000	–	–	0.03%	121
2019 Q1	$1.11M	Hold	212,000	–	–	0.02%	120
2018 Q4	$943K	Sell	212,000 -225,000	-51%	-$1.23M	0.02%	123
2018 Q3	$3.53M	Hold	437,000	–	–	0.04%	133
2018 Q2	$3.07M	Hold	437,000	–	–	0.04%	135
2018 Q1	$6.22M	Hold	437,000	–	–	0.08%	116
2017 Q4	$3.83M	Hold	437,000	–	–	0.05%	119
2017 Q3	$5.11M	Hold	437,000	–	–	0.05%	123
2017 Q2	$6.11M	Sell	437,000 -47,800	-10%	-$546K	0.06%	109
2017 Q1	$6.65M	Sell	484,800 -272,565	-36%	-$2.83M	0.08%	109
2016 Q4	$5.43M	Hold	757,365	–	–	0.07%	111
2016 Q3	$11.5M	Hold	757,365	–	–	0.13%	97
2016 Q2	$7.46M	Hold	757,365	–	–	0.08%	102
2016 Q1	$10.1M	Buy	+757,365	New	+$9.52M	0.11%	94

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

OrbiMed's SNDX Position: Q1 2026 in Review

OrbiMed opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 962,300 shares worth $22.5M. The stake represents 0.45% of the portfolio and ranks #53 among its holdings. This is a return to the name: OrbiMed previously reported a position in SNDX as recently as Q3 2024.

OrbiMed first reported a position in SNDX in Q1 2016 and has held it in 34 quarters since. The position peaked at $53M in Q2 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

OrbiMed held 962,300 shares of Syndax Pharmaceuticals worth $22.5M as of Q1 2026.
Syndax Pharmaceuticals was a new OrbiMed position in Q1 2026.
Syndax Pharmaceuticals made up 0.45% of OrbiMed's portfolio in Q1 2026, its #53 holding.
OrbiMed first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 34 quarters since.
OrbiMed's Syndax Pharmaceuticals position peaked at $53M in Q2 2023.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.